The health reform debate may have ended in Congress, but Eli Lilly and Co. remains active, sponsoring a talk about the positives of the
bill—and calling for further government efforts to help pharmaceutical research and development.
The company is seeing a rush of new sales for its Web-based electronic medical record system from doctors, who all stand to
receive bonus payments from the federal stimulus act for computerizing their patient records.
In the last 10 years, Indiana’s major research universities—Indiana and Purdue—have nearly doubled their
science-based research budgets, to a total of $895 million. Yet Indiana’s public universities still run in the middle
of the pack nationally.
The Roudebush Veterans Affairs Medical Center and the Indiana Health Information Exchange are going to work to make
their medical record systems talk to each other in a pilot project spearheaded by the U.S. Department of Veterans Affairs.
Even with debt levels at Eli Lilly and Co. at paltry lows, a string of bad news finally forced Standard & Poor’s
to lower
its rating on the company’s senior unsecured debt. But the New York-based agency said it believes the Indianapolis-based
drugmaker will eventually break its string of bad luck on developing new products.
Ben Bernanke may be worried about deflation in the economy, but there’s certainly no chance of it in health care and
insurance. Employers’ health plan premiums surged another 8 percent this year, according to results from a massive survey
by Indianapolis-based United Benefit Advisors.
New student-lending rules proposed by the Obama administration could wipe out as much as two-thirds of profits at Carmel-based
ITT Educational Services Inc., some analysts believe.
St. Vincent Health is moving aggressively to expand its transplant program in a direct challenge to Clarian Health’s dominance
in the field. The Indianapolis-based hospital system filed in July for permission to conduct pancreas transplants. And down
the road, it’s eyeing liver and maybe even lung transplants.
What a tough week for Lilly. On Aug. 12, a judge struck down the Indianapolis-based drugmaker’s U.S. patent on Strattera,
which might cost the company about $450 million in annual revenue. Then, five days later, Lilly halted clinical trials on
one
of its experimental Alzheimer’s medicines, because patients did worse on the drug than on a placebo.
Dr. Kevin Macadaeg, vice president of the Indiana Spine Group, talked about his physician
group's decision to build a 60,000-square-foot medical office and "bioskills" lab in Carmel next year, as well
as the group's commitment to grow independently in the face of pressures from hospital acquisitions and health reform.
Monroe Hospital in Bloomington is the latest target in the statewide buildup by hospital systems. St. Vincent Health, St.
Francis and at least one other system have all had talks in the past month with Monroe.
Indianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it’s hard to picture what the company will look like in five years.
The health care industry is responding to reforms that will pay doctors bonuses if they provide high-quality care and save
Medicare money.
An experimental medicine for hepatitis C that Lilly helped identify and develop is now on the cusp of market approval, with
analysts predicting as much as $2 billion in annual U.S. sales.
Roche Diagnostics, a Swiss company that keeps its U.S. headquarters in Indianapolis, has been sued for marking its Accu-Chek
blood glucose monitors and accessories with patents that are expired. Illinois resident David O’Neill has sued on behalf
of the U.S. government to recover damages of $500 per infraction.
ABC station did not renew Todd Wallace's contract after three years, instead recruiting Todd Connor, an ABC News correspondent.
Wallace's co-anchor, Trisha Shepherd, will stay on.
Eli Lilly and Co.’s loss of a patent on one of its blockbuster drugs in court late last month received a collective yawn
from
investors, who have shunned the stock because of five looming patent expirations.
Trustee Brian Bash has sent letters to politicians who he says received a total of $900,000 in funds Durham had borrowed
from the coffers of Fair Finance, a now-bankrupt investment firm based in Ohio.
Emmis Communications Corp. on Tuesday postponed a decision on CEO Jeff Smulyan's bid to take the company private, saying
it did not receive enough votes from shareholders to reach a quorum.
The Carmel-based life and health insurer earned $33.1 million in the three months ended June 30, or 12 cents per diluted share.
Excluding losses on investments and retired debt, the company would have earned 16 cents per share.
